| Laura L. Godlewski |
Laura L. Godlewski is Senior Vice President-Finance & Administration at HTG Molecular Diagnostics, Inc.
She received an undergraduate degree from Michigan State University. |
| John L. Lubniewski |
John L. Lubniewski is President, Chief Executive Officer & Director at HTG Molecular Diagnostics, Inc.
In the past Mr. Lubniewski occupied the position of Director-New Business Development at Corning, Inc., Senior Vice President for Ventana Medical Systems, Inc. and Principal at Hoffmann-La Roche, Inc.
Mr. Lubniewski received an undergraduate degree from Clarkson University. |
| Byron T. Lawson |
Byron T. Lawson is Chief Commercial Officer & Senior Vice President at HTG Molecular Diagnostics, Inc. |
| Ann F. Hanham |
Ann F. Hanham founded InterMune, Inc. Presently, she is Chairman of HTG Molecular Diagnostics, Inc. She is also on the board of SCYNEXIS, Inc.
In the past she held the position of Chairman at Adlyfe, Inc., Managing Director & General Partner at Burrill LLC, Senior Manager-Medical Affairs at Becton, Dickinson & Co., Managing Director & Founding Partner at BAR Capital Management LLC, Managing Partner at Bar Capital LLC, Medical Director at Celtrix Pharmaceuticals, Inc., Vice President-Clinical & Regulatory Affairs at InterMune, Inc. and Senior Director-Oncology Product Development at Otsuka America Pharmaceutical, Inc.
Dr. Hanham received a doctorate from the University of British Columbia, a graduate degree from Simon Fraser University and an undergraduate degree from the University of Toronto. |
| Michelle R. Griffin |
Michelle R. Griffin is on the board of HTG Molecular Diagnostics, Inc., Adaptive Biotechnologies Corp., Acer Therapeutics, Inc. and Chinook Therapeutics, Inc.
In her past career she held the position of Principal at Pacific Biotechnology Consulting Group, Chairman at Universal Cells, Inc., Senior VP, Chief Executive & Operating Officer at Emergent Product Development Seattle, Chief Operating Officer & Senior Vice President for Emergent Product Development Seattle, Chief Financial Officer of Corixa Corp., Chief Financial Officer & Senior Vice President at Dendreon Corp., Chief Financial Officer & Executive Vice President of OncoGenex Pharmaceuticals, Inc. and Controller for Corixa Corp.
She received an MBA from Seattle University and an undergraduate degree from George Mason University. |
| James T. LaFrance |
Founder of Lafrance Consulting LLC, James T. LaFrance is on the board of Aspira Women's Health, Inc. (former Chairman), HTG Molecular Diagnostics, Inc., Personal Genome Diagnostics, Inc. and LightIntegra Technology, Inc. He previously occupied the position of President & Chief Executive Officer at Lafrance Consulting LLC, Chief Executive Officer for Omnyx LLC, Chief Executive Officer at Vermilion, Inc. and General Manager at Ventana Medical Systems, Inc.
James T. LaFrance received an undergraduate degree from the University of Connecticut and an MBA from the University of Notre Dame. |
| Donnie M. Hardison |
Founder of Dmh Consulting Group, LLC, Donnie M. Hardison is on the board of HTG Molecular Diagnostics, Inc. and 10 other companies. In his past career he was President, Chief Executive Officer & Director at EXACT Sciences Corp., Chief Operating Officer & Executive Vice President at Laboratory Corp. of America Holdings, Senior Vice President-Sales & Marketing at Quest Diagnostics, Inc., Vice President-Sales & Marketing at GSK Plc, President, Chief Executive Officer & Director at Biotheranostics, Inc., Director at Good Start Genetics, Inc., Partner at Siebel Systems, Inc. and Managing Partner at OnTarget, Inc.
He received an undergraduate degree from The University of North Carolina at Charlotte. |
| Lee Roy McCracken |
Lee Roy McCracken is a businessperson who has been at the head of 6 different companies. Presently, he holds the position of Chairman for Global Medical & Research Technologies, Inc. and Chief Executive Officer & Director at Drawbridge Health, Inc. Mr. McCracken is also on the board of HTG Molecular Diagnostics, Inc.
In his past career he held the position of Chief Executive Officer at Gensignia Life Sciences, Inc., Chief Executive Officer of Nephrosant, Inc., President & Chief Executive Officer of Pathwork Diagnostics, Inc., President & Chief Business Officer at Corautus Genetics, Inc., Director-Business Development-Americas Region at Allergan, Inc., Senior Vice President-Corporate Development of CombiChem, Inc., Senior VP-Pharmaceutical Business Development at Diversa Corp., Principal at Union Venture Capital Corp., Vice President-Development at Prometheus Laboratories, Inc. and Managing Director at Pacific Pharma LP.
Mr. McCracken received a graduate degree from the University of Dayton, an undergraduate degree from Santa Clara University and an MBA from Anderson School of Management. |
| Harry Allan George |
Founder of Solstice Capital LLC, Interleaf, Inc., Kurzweil Technologies, Inc. and Radiance Therapeutics, Inc., Harry Allan George is Managing General Partner at Solstice Capital LLC. He is also Director & Member at Southern Arizona Leadership Council and on the board of 9 other companies.
In the past Mr. George occupied the position of Director at Radiance Therapeutics, Inc., Director & Vice President-Finance at Kurzweil Technologies, Inc., Chairman of SynCardia Systems LLC and Director & Vice President-Finance at Interleaf, Inc.
He received an undergraduate degree from Bowdoin College and an MBA from the University of Arizona. |
